Evidence – Exploring the CombiCell Platform to Provides a Clinically Relevant Antigen-Biology Layer for Immunotherapy Discovery

• Immunotherapy response is governed by antigen density thresholds, not binary target presence – yet discovery still relies on cell lines that sit far above clinical densities, hiding the low-density and relapse conditions where CAR-T, TCEs and multi-specifics actually fail.
• CombiCell allows display of one or more targets on cells at precise, tunable densities in minutes rather than months – spanning the full clinical range, free of genetic drift, and reaching the ultra-low densities beyond the limits of flow cytometry.
• This transforms antigen density into a controllable experimental variable across modalities, grounding in vitro discovery R&D in clinical relevant target densities

Speakers:

Phil Jakeman

Chief Executive Officer

Matchbio